TEVA PHARMACEUTICALS USA, INC. for TEVA PHARMACEUTICALS USA INC

Pharmacy PHA

Drug Safety and Accountability Act (proposal from 111th Congress); S.330, Consumer Protection Recall Act of 2011; Medicaid pharmacy issues.

Foreign entity interest: Teva Pharmaceuticals Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA, Inc. has an indirect interest in the issues listed above.

Contacted: Patent & Trademark Office (PTO); White House Office; Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR)

Bills named: S. 330 (112th)

Copyright/Patent/Trademark CPT

S.23, Patent Reform Act of 2011; H.R. 1249, America Invents Act of 2011; and S.27, Preserve Access to Affordable Generics Act

Foreign entity interest: Teva Pharmaceuticals Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA, Inc. has an indirect interest in the issues listed above.

Contacted: Centers For Medicare and Medicaid Services (CMS); White House Office; SENATE; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Patent & Trademark Office (PTO); U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS)

Bills named: H.R. 1249 (112th), S. 23 (112th), S. 27 (112th)

Trade (domestic/foreign) TRD

U.S - Israel Trade Agreement; Trans-Pacific Partnership Trade Agreement

Foreign entity interest: Teva Pharmaceuticals Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA, Inc. has an indirect interest in the issues listed above.

Contacted: Food & Drug Administration (FDA); U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS); White House Office; Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Patent & Trademark Office (PTO); SENATE

Health Issues HCR

Funding for FDA Office of Generic Drugs; S.296. Preserving Access to Life-Saving Medications Act; women's issues relating to healthcare reform law; implementation of biologics provisions of healthcare reform law; H.R.5, Help Efficient Accessible Low-Cost Timely Healthcare (HEALTH) Act of 2011; prescription drug abuse/diversion proposals; S.1357, Affordable Medicines Utilization Act of 2011; S.1882, Fair & Immediate Release of Generic Drugs Act; H.R.4332, Generic Drug Application Review Fairness Act

Foreign entity interest: Teva Pharmaceuticals Industries, Ltd., as an indirect parent of Teva Pharmaceuticals USA, Inc. has an indirect interest in the issues listed above.

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Patent & Trademark Office (PTO); White House Office; U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS); SENATE; Centers For Medicare and Medicaid Services (CMS)

Bills named: S. 1357 (112th), H.R. 5 (112th), S. 1882 (112th), H.R. 4332 (112th), S. 296 (112th)